Even in melanoma, where many RCTs of IFN have been performed, evidence supporting a specific IFN dose, duration, or formulation and identification of subsets of patients beyond those with detectable residual disease most likely to benefit remain debatable issues, with no RCT showing additional benefit for treatment extending beyond 12 to 18 months.19,33 For osteosarcoma, such evidence is completely absent. The gene discussed is IFNA1; the disease is melanoma.